Walmart builds green rep with opening of 100th solar store
SAN DIEGO — Walmart has unveiled its 100th solar-powered store in San Diego. By working with California-based SolarCity, the company’s focus on solar power has generated more than 3,000 contract construction jobs in California. In turn, SolarCity has hired 1,213 employees since announcing its first Walmart projects in September 2010. The San Mateo, Calif.-based company will install, manage and maintain 70-of-the-100 new solar power systems.
“At Walmart, we believe sustainability is about living better,” said Kimberly Sentovich, SVP Pacific division for Walmart. “By using one of California’s greatest resources – sunshine – and employing renewable technology with our California-based partners, we will continue developing solutions that are both good for the environment and good for business.”
The total combined solar efforts in California are expected to:
Generate up to 70 million kilowatt hours of clean, renewable energy per year;
Avoid producing more than 21,700 metric tons of carbon dioxide emissions per year; and
Provide 10% to 30%of each facility’s total electricity needs.
“Walmart is showing other businesses that you can create jobs and reduce air pollution by using better energy,” SolarCity CEO Lyndon Rive said. “In Walmart, other businesses seeking efficiency and smart energy policy have a strong example to follow.”
There now are 100 Walmart stores and Sam’s Clubs in California using traditional and thin film solar installations. After launching its solar pilot program in May 2007, Walmart strengthened its commitment to renewable energy in the state of California last year when it announced plans to expand its solar portfolio to more than 75% of its stores in California, approximately 130 stores, by the end of 2013. Since then the company has worked with local companies to install solar technology at stores from Chico to San Diego.
“Walmart’s solar power initiatives shows how companies can help bring cost-effective energy solutions to scale as part of ‘business-as-usual,’” said Gwen Ruta, VP Environmental Defense Fund’s Corporate Partnership Program. “This milestone for Walmart’s efforts demonstrates the growing roles for renewables in America’s energy future.”
CouponCabin survey unveils tablet owners’ shopping habits
WHITING, Ind. — Tablet owners spend a fair amount of time on their devices, particularly to shop online or redeem coupons.
According to a new CouponCabin survey, 1-in-5 U.S. adults own and use a tablet computer such as an iPad, Kindle Fire or Xoom. Among them, those ages 35 to 44 years reported the highest instance of tablet ownership (29%). And while most tablet owners spend less than an hour using their device (53%), 47% said they use their tablet for an hour to less than two hours, while 16% use their tablet for two hours or more. Despite the disparity in time spent using the tablet, nearly one-third of tablet owners (32%) reported their favorite activity on their device is online shopping, while 35% of tablet owners have redeemed a coupon using their tablet. In addition, nearly 6-in-10 tablet owners (57%) said they shop on their device while watching TV.
The survey was conducted online within the United States by Harris Interactive on behalf of CouponCabin from June 20 to 22, among 2,214 U.S. adults ages 18 years and older.
Abon seeks approval for generic leukemia drug
NORTHVALE, N.J. — Abon Pharmaceuticals is challenging the patent protection on an injected drug used to treat leukemia in children and adolescents, the company said Tuesday.
Abon said it filed with the Food and Drug Administration for regulatory approval of clofarabine in the 1 mg-per-mL strength. The drug is a generic version of Genzyme’s Clolar, used to treat relapsed or refractory acute lymphoblastic leukemia in patients ages one to 21 years, who already have undergone at least two regimens.
Genzyme, now part of French drug maker Sanofi, filed suit against Abon on Friday in the U.S. District Court for the District of New Jersey to prevent the commercialization of the generic drug before the expiration of U.S Patent No. 5,661,136, which takes place in 2018. As the first company to file an approval application with the FDA for a generic version of Clolar, Abon would be entitled to 180 days in which to compete exclusively against the branded version of the drug.
Clolar had sales of $77.5 million during the 12-month period ended in June, according to IMS Health.